GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
L

Labgenomics Co 084650.KQ · KRW

Health Care · KOSDAQ · 🇰🇷 South Korea

Compare

1,872

-1.16%

Close of 9 Nov 2026, in KRW

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Labgenomics Co

Its shares trade on KOSDAQ under the ticker 084650.KQ. It has been listed since 1 July 2013. In the fiscal year to 31 December 2025, it reported revenue of ₩88.16bn and a net loss of ₩64.37bn. At that date it held total assets of ₩230.15bn and shareholders' equity of ₩149.62bn.

LabGenomics Co., Ltd. engages in the provision of vitro diagnostic products and services. The company is headquartered in Seongnam, Gyeonggi-Do. The company went IPO on 2013-07-01. The firm mainly provides IVD services, including general diagnostic check services, molecular diagnostic check services, and research and development services. The Company’s IVD products include deoxyribonucleic acid (DNA) chips, polymerase chain reaction (PCR) kits and others. The company also provides examination for breast cancer and colorectal cancer, biosensor for point of care testing (POCT) and others. The company also provides healthy food.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
1 Jul 2013

Leadership

Pay as last reported

  • Jae Hak RyuChief Executive Officer, Director, since 2025
  • Mr. Jae Hyeong JangInternal Auditor
  • Ji Wung ChoiDirector
  • Myeong Sin KimDirector
  • Mr. Gyu Yeong KimNon-Executive Independent Director
  • Mr. Yu Chan KimNon-Executive Independent Director
  • Mr. Yeong Yeop ParkNon-Executive Independent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Labgenomics Co Ltd provides IVD services including molecular diagnostic check services.
  • The firm offers DNA chips and polymerase chain reaction PCR kits.
  • Examination for breast cancer and colorectal cancer is part of the portfolio.

Weaknesses

  • The company is headquartered in Seongnam, Gyeonggi-Do, which limits local visibility.
  • Labgenomics Co Ltd listed on 1 July 2013, showing limited market history.
  • Healthy food is a minor product compared to core diagnostic services.

Opportunities

  • Expansion of biosensor for point of care testing POCT services is possible.
  • Research and development services can drive innovation in molecular diagnostics.
  • Increasing demand for general diagnostic check services offers growth potential.

Threats

  • Competition in the Health Care sector may reduce market share.
  • Regulatory changes in South Korea could impact IVD product approvals.
  • Economic downturns might decrease spending on non-essential healthy food items.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.